Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 6
2021 5
2022 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Predictive factors for false negatives following sentinel lymph node biopsy in early oral cavity cancer.
Miura K, Kawakita D, Oze I, Suzuki M, Sugasawa M, Endo K, Sakashita T, Ohba S, Suzuki M, Shiotani A, Kohno N, Maruo T, Suzuki C, Iki T, Hiwatashi N, Matsumoto F, Kobayashi K, Toyoda M, Hanyu K, Koide Y, Murakami Y, Hasegawa Y. Miura K, et al. Among authors: hanyu k. Sci Rep. 2022 Apr 28;12(1):6917. doi: 10.1038/s41598-022-10594-1. Sci Rep. 2022. PMID: 35484369 Free PMC article. Clinical Trial.
Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
Okada T, Fushimi C, Matsuki T, Okamoto I, Sato H, Kondo T, Tokashiki K, Kishida T, Ito T, Yamashita G, Aihara Y, Hanyu K, Kushihashi Y, Masubuchi T, Tada Y, Miura K, Harada Y, Momiyama K, Yamashita T, Omura GO, Takahashi H, Oridate N, Tsukahara K. Okada T, et al. Among authors: hanyu k. Anticancer Res. 2022 Mar;42(3):1607-1613. doi: 10.21873/anticanres.15635. Anticancer Res. 2022. PMID: 35220258
Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study.
Okada T, Fushimi C, Matsuki T, Tokashiki K, Takahashi H, Okamoto I, Sato H, Kondo T, Hanyu K, Kishida T, Ito T, Yamashita G, Masubuchi T, Tada Y, Miura K, Omura GO, Yamashita T, Oridate N, Tsukahara K. Okada T, et al. Among authors: hanyu k. Anticancer Res. 2023 Jun;43(6):2717-2724. doi: 10.21873/anticanres.16438. Anticancer Res. 2023. PMID: 37247908
Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study.
Yasumatsu R, Shimizu Y, Hanai N, Kariya S, Yokota T, Fujii T, Tsukahara K, Ando M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Yonekura S, Asakage T, Nekado T, Yamada T, Homma A. Yasumatsu R, et al. Among authors: hanyu k. Int J Clin Oncol. 2022 Jan;27(1):95-104. doi: 10.1007/s10147-021-02047-y. Epub 2021 Nov 13. Int J Clin Oncol. 2022. PMID: 34773525 Free PMC article.
Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.
Niwa K, Kawakita D, Nagao T, Takahashi H, Saotome T, Okazaki M, Yamazaki K, Okamoto I, Hirai H, Saigusa N, Fushimi C, Masubuchi T, Miura K, Okazaki SI, Matsui H, Okada T, Iwaki S, Matsuki T, Hanyu K, Tsukahara K, Oridate N, Tada Y. Niwa K, et al. Among authors: hanyu k. Sci Rep. 2020 Oct 12;10(1):16988. doi: 10.1038/s41598-020-73965-6. Sci Rep. 2020. PMID: 33046752 Free PMC article.
18 results